Food and Drug Administration approval was based on data in five patients with ASM from a phase 2 study and several case studies demonstrating that imatinib was effective in treating patients with ASM with KIT mutations other than D816V, including F522C and K509I (25–27). Here, KIT is linked to aggressive systemic mastocytosis.